-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Braxia Scientific Corp. (OTCPK:BRAXF) (CSE:RAX) (FWB:4960) recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended March 31, 2021. On a year-over-year basis, revenue increased 47.5%.
Fiscal 2022 Financial Highlights
-
In the fourth quarter of fiscal 2022, the company recorded revenue of $369,654 compared with revenue of $246,673 in the fourth quarter of 2021. On a year-over-year basis, fourth quarter revenues increased 49.9%.
-
The increase in revenue primarily reflects an increase in the number of treatments from the administering of ketamine at the Braxia Health clinics in Ontario.
-
Net loss was $12.1 million for the year ended March 31, 2022, compared to a net loss of $88.8 million for the year ended March 31, 2021.
-
The company's cash and cash equivalents as of March 31, 2022 was $8.6 million compared with December 31, 2021 at $7.64 million reflecting the impact of a private placement the company closed on January 31, 2022.
"We have established Braxia as a trusted and advanced clinic group and research platform enabling us to deliver on our vision to provide significantly greater access to innovative ketamine treatments for depression. We have also expanded our clinic footprint and launched several research initiatives to provide access to novel treatments such as psilocybin," stated Dr. Roger McIntyre, CEO, Braxia Scientific.
Management Changes
Jason Wolkove, joins Braxia as chief information officer, and Daniel Herrera, joins as vice president, research & development and growth.
Photo: Benzinga; Sources: courtesy of Tumisu, sergeitokmakov via Pixabay
Related News
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Â
Braxia Scientific Corp. (OTCPK:BRAXF) (CSE:RAX) (FWB:4960) recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended March 31, 2021. On a year-over-year basis, revenue increased 47.5%.
布拉夏科学公司(OTCPK:BRAXF)(CSE:RAX)(FWB:4960)已记录149万美元的收入对于2022财年截至2022年3月31日的年度收入为100.8万美元,而截至2021年3月31日的年度收入为100.8万美元。与去年同期相比,收入增长47.5%。
Fiscal 2022 Financial Highlights
2022财年财务亮点
-
In the fourth quarter of fiscal 2022, the company recorded revenue of $369,654 compared with revenue of $246,673 in the fourth quarter of 2021. On a year-over-year basis, fourth quarter revenues increased 49.9%.
-
The increase in revenue primarily reflects an increase in the number of treatments from the administering of ketamine at the Braxia Health clinics in Ontario.
-
Net loss was $12.1 million for the year ended March 31, 2022, compared to a net loss of $88.8 million for the year ended March 31, 2021.
-
The company's cash and cash equivalents as of March 31, 2022 was $8.6 million compared with December 31, 2021 at $7.64 million reflecting the impact of a private placement the company closed on January 31, 2022.
-
在2022财年第四季度,该公司的收入为369,654美元,而2021年第四季度的收入为246,673美元。与去年同期相比,第四季度的收入增长了49.9%。
-
收入的增加主要是因为安大略省布拉夏保健诊所的氯胺酮治疗次数增加。
-
净亏损12.1美元 百万截至2022年3月31日的年度,相比之下,截至2021年3月31日的年度净亏损8880万美元。
-
该公司的现金和现金等价物截至2022年3月31日是860万美元与2021年12月31日相比,该公司于2022年1月31日完成了764万美元的私募,反映了私募的影响。
"We have established Braxia as a trusted and advanced clinic group and research platform enabling us to deliver on our vision to provide significantly greater access to innovative ketamine treatments for depression. We have also expanded our clinic footprint and launched several research initiatives to provide access to novel treatments such as psilocybin," stated Dr. Roger McIntyre, CEO, Braxia Scientific.
我们已经建立了Braxia作为一个值得信赖的先进的临床小组和研究平台,使我们能够实现我们的愿景,为抑郁症提供更多的创新型氯胺酮治疗方法。我们还扩大了我们的诊所足迹,并推出了几项研究计划,以提供新的治疗方法,如裸盖菇素。罗杰·麦金太尔博士布拉夏科学公司首席执行官。
Management Changes
管理层变动
Jason Wolkove, joins Braxia as chief information officer, and Daniel Herrera, joins as vice president, research & development and growth.
贾森·沃尔科夫,加盟Bracia担任首席信息官,以及丹尼尔·赫雷拉,加盟副总裁,负责研发和增长。
Photo: Benzinga; Sources: courtesy of Tumisu, sergeitokmakov via Pixabay
图片:Benzinga;来源:Tumisu,Sergeitokmakov通过Pixabay提供
Related News
相关新闻
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
加拿大特别准入计划进一步批准用于紧急治疗的新型致幻药物
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Bracia在安大略省开设新诊所,为进一步获得氯胺酮和裸盖菇素治疗提供便利
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
激动:埃隆·马斯克讨论迷幻药,Delix筹集7000万美元,MindCure研究MDMA治疗女性性功能障碍
Â
Â
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧